Armistice Capital »

Aeglea Biotherapeutics shares owned by Armistice Capital

Quarter-by-quarter ownership of Aeglea Biotherapeutics (SYRE) shares owned by Armistice Capital from 13F filings

Historical chart of Armistice Capital investment in Aeglea Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aeglea Biotherapeutics held by Armistice Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aeglea Biotherapeutics by Armistice Capital

Quarter filed Position value Share count Share price at filing
2024-06-30 $3.2M 136k 23.51

More positions owned by Armistice Capital

Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Ishares Tr Russell 2000 Etf Put Option (IWM)
Ptc Therapeutics I (PTCT)
Cytokinetics Com New (CYTK)
Supernus Pharmaceuticals (SUPN)
Neurocrine Biosciences (NBIX)
Incyte Corporation (INCY)
Immunovant (IMVT)
Agios Pharmaceuticals (AGIO)
Argenx Se Sponsored Adr (ARGX)
Novo-nordisk A S Adr (NVO)
Sanofi Sponsored Adr (SNY)
Alkermes SHS (ALKS)
Medtronic SHS (MDT)
Aurinia Pharmaceuticals (AUPH)

View all positions for Armistice Capital

Top funds holding Aeglea Biotherapeutics

Fairmount Funds Management
Perceptive Advisors
VR Adviser
BlackRock
BlackRock
Braidwell
Commodore Capital
Vanguard Group
Deep Track Capital
State Street Corporation
Paradigm Biocapital Advisors
Assenagon Asset Management
Goldman Sachs Group
Geode Capital Management
Pictet Asset Management Holding SA

View all funds holding Aeglea Biotherapeutics